Sign up for The Real Eisman Playbook Premium at https://premium.realeismanplaybook.com/ On episode 50 of The Real Eisman Playbook, Steve Eisman sits down with Mark Cuban to discuss why prescription drug prices in the U.S. remain so high and what can be done to fix the system. Cuban explains how pharmacy benefit managers (PBMs) shape drug pricing behind the scenes and why he believes the current structure is fundamentally broken. The conversation also dives into his efforts to disrupt the industry through Cost Plus Drugs and bring transparent pricing to consumers. 00:00 - Intro 02:05 - The Problems with the Healthcare Industry 08:50 - How PBMs Actually Work 22:26 - Cost Plus Drugs 31:20 - The Impact Cost Plus Drugs Has Had in the Industry 33:40 - Cost Plus Wellness 37:53 - Hopes For Growth 40:18 - What Mark's Learned From the Mavericks and Shark Tank 42:30 - Mark's Thoughts on Today's Market 46:10 - The Message Mark Wants People To Know About Cost Plus Drugs 47:03 - Outro Subscribe 👉🏻https://www.youtube.com/@RealEismanPlaybook?sub_confirmation=1 Connect with Steve Eisman and access all things The Eisman Playbook: 🌐 https://linktr.ee/realeismanplaybook → Follow on socials, watch episodes, and get the latest updates — all in one place. Disclaimer: The financial opinions expressed are for information purposes only. The opinions expressed by the hosts and participants are not an attempt to influence specific trading behavior, investments, or strategies. Past performance does not necessarily predict future outcomes. No specific results or profits are assured when relying on this content. Before making any investment or trade, evaluate its suitability for your circumstances and consider consulting your own financial or investment advisor. The financial products discussed in ‘The Eisman Playbook' carry a high level of risk and may not be appropriate for many investors. If you have uncertainties, it's advisable to seek professional advice. Remember that trading involves a risk to your capital, so only invest money you can afford to lose. Derivatives are unsuitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell, or retain any specific investment or service. Copyright ©2025 Steve Eisman #wallstreet #finance #businessnews #investing #businesspodcast #investment #financepodcast #stockmarket